Pembrolizumab alone

DRUG3 trials

Sponsors

Prof. Dr. med. Dirk Schadendorf, National Cancer Centre, Singapore, Precigen, Inc

Conditions

Cervical CancerColorectal CancerHPV-Related CarcinomaHPV-Related MalignancyMalignant MelanomaMetastatic Cervical CancerRecurrent Cervical Carcinoma

Phase 1

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

CompletedNCT02902042

Prof. Dr. med. Dirk SchadendorfMalignant Melanoma

Start: 2018-04-24End: 2020-11-30Updated: 2021-02-16

Phase 2

Window of Opportunity Study in Colorectal Cancer

CompletedNCT03984578

National Cancer Centre, SingaporeColorectal Cancer

Start: 2019-06-12End: 2025-02-28Updated: 2025-11-18

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

RecruitingNCT06157151

Precigen, IncCervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy +2

Start: 2025-03-21End: 2028-01-30Target: 46Updated: 2025-11-14

Related Papers

PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

Cancer Immunology Immunotherapy2025-03-215 citations

A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2024-06-011 citations

Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.

2021-10-1317 citations

Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.

Journal of Clinical Oncology2021-05-204 citations